fbpx
QUESTIONS? CALL (202)-802-8877

SOLID TUMOR MOLECULAR PROFILE FULL GENE LIST

Pmcdx's Solid Tumor Molecular Profile targets 170 cancer-related genes carefully selected to provide comprehensive and efficient analysis of therapeutically relevant alterations as well as those being studied in current and upcoming clinical trials. Our expert curation team creates each report considering the mutational status of all tested genes, resulting in a personalized profile including recommendations for approved therapies, counter-indicated therapies, off-label options, and active trials. With this powerful tool in hand, patients and care teams are armed with the best information possible to navigate the increasingly complex battle against cancer.

HIGLIGHTS

  • Highly selective gene list based on the latest
    research
  • Simultaneous analyses of DNA and RNA
    • RNA allows for optimal detection of
      gene fusions
  • Tumor mutation burden analysis
  • Competitive detection of a broad range of variant types
    • Single nucleotide variants
    • Small indels
    • Amplifications
    • Splice variants
    • Gene fusions (from 50 genes)

 

Order Options

Sequencing (included)
Del/Dup (included)

 

Genes

ABL1, AKT1, AKT2, AKT3, ALK, APC, AR, ARID1A, ATM, ATR, AXL, BAP1, BARD1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BRIP1, BTK, CARD11, CCND1,
CCND2, CCND3, CCNE1, CD79A, CD79B, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK1, CHEK2, CREBBP, CSF1R, CTNNB1, DDR2,
DNMT3A, EGFR, EML4, EP300, ERBB2, ERBB3, ERBB4, ERCC1, ERCC2, ERG, ESR1, ETS1, ETV1, ETV4, ETV5, EWSR1, EZH2, FAM175A, FANCI,
FANCL, FBXW7, FGF1, FGF10, FGF14, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLI1, FLT1,
FLT3, FOXL2, GEN1, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, INPP4B, JAK2, JAK3, KDR, KIF5B, KIT, KMT2A, KRAS, LAMP1, MAP2K1,
MAP2K2, MCL1, MDM2, MDM4, MET, MLH1, MLLT3, MPL, MRE11A, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL1, MYCN, MYD88, NBN,
NF1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PALB2, PAX3, PAX7, PDGFRA, PDGFRB, PIK3CA, PIK3CB,
PIK3CD, PIK3CG, PIK3R1, PMS2, PPARG, PPP2R2A, PTCH1, PTEN, PTPN11, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RAF1, RB1, RET, RICTOR,
ROS1, RPS6KB1, SLX4, SMAD4, SMARCB1, SMO, SRC, STK11, TERT, TET2, TFRC, TMPRSS2, TP53, TSC1, TSC2, VHL, XRCC2 ( 170 genes )

Coverage:

≥ 5% variant allele frequency
99% at ≥ 250x coverage

Specimen Requirements:

Adequate specimen volume must be submitted to ensure the highest quality of analysis.

  • Minimum: 20% tumor cell content

cancer trst

10 Unstained Slides
  • Positively charged, unbaked
  • 4 - 5 microns sections
  • Tissue surface area: ≥ 5mm x 5mm
  • Include 1 H&E slide if available
cancer test

cancer test

1 FFPE Tumor Block
  • Include 1 H&E slide if available
TOP